Lundbeck Defends Its Escitalopram Patent In Denmark, But Not In Spain
This article was originally published in The Pink Sheet Daily
Executive Summary
Lundbeck's top-selling product, Cipralex, is responsible for more than half its sales, but faces generic competition in Spain.
You may also be interested in...
Lundbeck’s New Partners: Research With Genmab, Marketing With Merck
Lundbeck has entered into a research collaboration with fellow Danish company Genmab, its first since announcing a new R&D strategy in September. It’s the second collaboration for Genmab since that company also updated its corporate strategy at around the same time.
Lundbeck’s New Partners: Research With Genmab, Marketing With Merck
Lundbeck has entered into a research collaboration with fellow Danish company Genmab, its first since announcing a new R&D strategy in September. It’s the second collaboration for Genmab since that company also updated its corporate strategy at around the same time.
Lundbeck's New Partnering Focus: Link Up With Genmab On Research And Merck On Marketing Sycrest
Lundbeck to collaborate on CNS research with fellow Danish firm Genmab, and to exclusively market Merck's antipsychotic Sycrest outside the U.S., China and Japan.